isotretinoin

(redirected from Amnesteem)
Also found in: Medical.
Related to Amnesteem: isotretinoin, Claravis, Sotret

i·so·tre·ti·noin

 (ī′sō-trĕt′n-oin′)
n.
A synthetic isomer of retinoic acid that inhibits sebaceous gland secretion and is used in the treatment of severe nodular acne. It can cause birth defects if taken during pregnancy.

[iso- + tretinoin, retinoic acid (t(rans)- + retino(ic acid) + -in).]

isotretinoin

(ˌaɪsəʊtrəˈtɪnəʊɪn)
n
(Pharmacology) a drug related to vitamin A, used to treat severe acne that has failed to respond to other treatment
Translations

isotretinoin

n isotretinoína
Mentioned in ?
References in periodicals archive ?
10 Mylan: Amnesteem Revenue ($m), AGR (%), CAGR (%), 2012-2024 Table 7.
Three versions of isotretinoin currently are on the market: Amnesteem, Sotret, and Claravis.
Isotretinoin is marketed under the names Roaccutane, Accutane, Amnesteem, Claravis, Clarus or Decutan and has been used to treat severe acne since the 1980s.
The FDA's listing will appear for searches for the drug under any of its four names, which include the Accutane brand name and generic versions Amnesteem, Claravis and Sotret.
A total of 19 pregnancies have been reported in patients on generic isotretinoin products since they have become available, with 18 reported for Amnesteem (Bertek), one for Claravis (Barr), and none for Sotret (Ranbaxy).
Other brands of isotretinoin include Amnesteem, Claravis and Sotret.
Amnesteem, the branded generic version of isotretinoin approved in November 2002 by the FDA, has a similar pregnancy prevention program.
By mid-month, supplies of Amnesteem were already on their way to wholesalers.
Once the program is fully implemented in December 2005, Accutane, Amnesteem, Claravis and Sotret can only be prescribed by prescribers who are registered and activated with the iPLEDGE program.
Over 50% of the increase in Brand Segment net revenues resulted from Amnesteem, which was launched in late fiscal 2003, with the remainder attributable to growth in the existing portfolio of products.
The unfavorable pricing on Amnesteem, as well as unfavorable pricing on Digitek(R), also as a result of increased competition, were the main reasons for the decrease in margin.